Human Mononuclear Cells from Peripheral Blood (hMNC-PB), pooled, ultra-pure

AcceGen Biotech Mononuclear Cells (MNC) represent the enriched lymphocyte and monocyte fraction of whole blood. They are isolated from umbilical cord blood and adult peripheral blood of healthy donors at AcceGen Biotech’s cell culture facility. Mononuclear Cells from cord blood contain a relatively high percentage of primitive progenitor cells, whereas Mononuclear Cells from adult peripheral blood (hMNC-PB) contain large numbers of mature immune cells.
Note: When culturing pooled hMNC-PB, a bidirectional allogeneic mixed lymphocyte reaction (MLR) is likely to occur during the first 48 hours. This will result in cell activation, blast transformation and T-cell proliferation. Thus, these cells are preferably used for several types of infectious virus tests, including neutralization assays. For HIV-related research, prior CD8+ T-cell depletion is recommended.
Freshly collected whole blood is carefully separated by optimized low-density gradient centrifugation, effectively removing the granulocytes. In order to avoid general cell damage, red blood cells are gently depleted by proprietary techniques instead of using classic osmotic lysis protocols. The obtained ultra-pure AcceGen Biotech Mononuclear Cells do not clump after thawing, and they exhibit superior viability and unchanged biological function.
Immediately after isolation, the freshly prepared Mononuclear Cells are cryopreserved using AcceGen Biotech’s proprietary, serum-free freezing medium, Cryo-SFM.Each cryo vial contains more than 25 million viable cells after thawing.

liquid nitrogen